For some people, a rare genetic mutation makes dementia inescapable. Three sisters have decided to confront fate with a genetic test and have joined a research project on possible treatments.
This week’s Medical Minute, discusses seizures experienced by Alzheimer’s patients and a novel peptide, which can be delivered via a nasal spray, that can tamp down this abnormal electrical activity and reduce resulting damage to brain cells.
A team at Stanford University has reversed memory loss in old mice by flooding their brains with spinal fluid taken from young animals. The finding may hold promise for Alzheimer's research.
Mild cognitive impairment, a common brain condition, can be an early sign of Alzheimer's disease. But most people don't know the symptoms. And some may mistake it for normal aging.
Novelist Amy Bloom talks about how, at her husband's insistence, she traveled with him to Zurich so he could legally terminate his life. Her new memoir is In Love.
Arts therapies appear to ease brain disorders from Parkinson's to PTSD. Now, artists and scientists have launched an effort to understand how these treatments change the brain.
Microglia are amoeba-like cells that scour the brain for injuries and invaders. But sometimes the usually helpful cells go into overdrive and damage the brain, researchers say.
Aduhelm is the first treatment approved in the country to slow cognitive decline in those living with Alzheimer's. Doctors have refused to prescribe it, given the lack of data and evidence behind it.
Alzheimer's researchers are trying new treatment approaches, including trying to boost the immune system, remove toxic tangles of protein and stimulate brain waves with light and sound.
Weeks after the Food and Drug Administration approved the Alzheimer's drug Aduhelm, doctors are struggling to figure out who should get the drug and how to use it safely.
Some patients who have had COVID-19 develop symptoms resembling early Alzheimer's. Researchers are trying to figure out whether these people are more likely to develop the disease itself.
A plaque-busting Alzheimer's drug called Aduhelm has yet to prove it can preserve memory and thinking. Even so, its approval by the Food and Drug Administration is making some patients opitimistic.
In his resignation letter, Dr. Aaron Kesselheim calls it "probably the worst drug approval decision in recent U.S. history." An FDA official says the agency found the benefits outweighed the risks.
The FDA has until Monday to decide whether to approve the first new Alzheimer's drug in nearly two decades. Two big studies of the drug produced conflicting results.
